Health and Safety Data Reporting; Addition of 20 High-Priority Substances and 30 Organohalogen Flame Retardants; Extension of Submission Deadline, 54386-54390 [2021-21164]
Download as PDF
<![CDATA[
54386
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Rules and Regulations
that it receives from the final recovery
or disposal facility within one year of
shipment delivery to the final recovery
or disposal facility that performed one
of recovery operations R1 through R11,
or RC1, or one of disposal operations D1
through D12, or DC1 to DC2, to the
competent authority of the country of
export that controls the shipment as an
export of hazardous waste, and on or
after the electronic import-export
reporting compliance date, to EPA
electronically using EPA’s Waste Import
Export Tracking System (WIETS), or its
successor system. The recovery and
disposal operations in this paragraph
are defined in 40 CFR 262.81.
*
*
*
*
*
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 716
[EPA–HQ–OPPT–2020–0474; FRL–8204–02–
OCSPP]
RIN 2070–AB11
Health and Safety Data Reporting;
Addition of 20 High-Priority
Substances and 30 Organohalogen
Flame Retardants; Extension of
Submission Deadline
Environmental Protection
Agency (EPA).
ACTION: Final rule; extension of
submission deadline.
AGENCY:
EPA is amending the deadline
for reporting pursuant to the Toxic
Substances Control Act (TSCA) Health
and Safety Data Reporting rule, which
requires manufacturers (including
importers) of 50 specified chemical
substances to report certain lists and
copies of unpublished health and safety
studies to EPA. Specifically, EPA will
be amending the deadline from
September 27, 2021 to December 1, 2021
for 20 of the 50 chemical substances and
to January 25, 2022 for 30 of the 50
chemical substances. The Health and
Safety Data Reporting Rule,
promulgated pursuant to TSCA section
8(d), requires manufacturers (including
importers) of certain chemical
substances to submit lists and copies of
certain unpublished health and safety
studies to EPA.
DATES: This final rule is effective
October 1, 2021.
ADDRESSES: The docket for this action,
identified by docket identification (ID)
number EPA–HQ–OPPT–2020–0474, is
available at https://www.regulations.gov
or at the Office of Pollution Prevention
and Toxics Docket (OPPT Docket),
Environmental Protection Agency
Docket Center (EPA/DC), West William
Jefferson Clinton Bldg., Rm. 3334, 1301
Constitution Ave. NW, Washington, DC.
Please note that due to the public
health concerns related to COVID–19,
the EPA Docket Center (EPA/DC) and
Reading Room is closed to visitors with
limited exceptions. The staff continues
to provide remote customer service via
email, phone, and webform. For the
latest status information on the EPA/DC
and docket access, visit https://
www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
For technical information contact:
Virginia Lee, Data Collections Branch,
Data Gathering and Analysis Division
(7410M), Office of Pollution Prevention
and Toxics, Environmental Protection
SUMMARY:
PART 265—INTERIM STATUS
STANDARDS FOR OWNERS AND
OPERATORS OF HAZARDOUS WASTE
TREATMENT, STORAGE, AND
DISPOSAL FACILITIES
7. The authority citation for part 265
continues to read as follows:
■
Authority: 42 U.S.C. 6905, 6906, 6912,
6922, 6923, 6924, 6925, 6935, 6936, and
6937.
8. Revise § 265.12(a)(4)(ii) to read as
follows:
■
§ 265.12
Required notices.
(a) * * *
(4) * * *
(ii) If the facility performed any of
recovery operations R12, R13, or RC3, or
disposal operations D13 through D15,
promptly send copies of the
confirmation of recovery or disposal
that it receives from the final recovery
or disposal facility within one year of
shipment delivery to the final recovery
or disposal facility that performed one
of recovery operations R1 through R11,
or RC1, or one of disposal operations D1
through D12, or DC1 to DC2, to the
competent authority of the country of
export that controls the shipment as an
export of hazardous waste, and on or
after the electronic import-export
reporting compliance date, to EPA
electronically using EPA’s Waste Import
Export Tracking System (WIETS), or its
successor system. The recovery and
disposal operations in this paragraph
are defined in 40 CFR 262.81.
[FR Doc. 2021–21417 Filed 9–30–21; 8:45 am]
BILLING CODE 6560–50–P
VerDate Sep<11>2014
16:40 Sep 30, 2021
Jkt 256001
PO 00000
Frm 00048
Fmt 4700
Sfmt 4700
Agency, 1200 Pennsylvania Ave. NW,
Washington, DC 20460–0001; telephone
number: (202) 564–4142; email address:
lee.virginia@epa.gov.
For general information contact: The
TSCA-Hotline, ABVI-Goodwill, 422
South Clinton Ave., Rochester, NY
14620; telephone number: (202) 554–
1404; email address: TSCA-Hotline@
epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by
this action if you manufacture (defined
by statute to include import) any of the
chemical substances that are listed in 40
CFR 716.120(d) of the regulatory text of
this document. The following list of
North American Industrial
Classification System (NAICS) codes is
not intended to be exhaustive, but rather
provides a guide to help readers
determine whether this document
applies to them. Potentially affected
entities may include: Chemical
manufacturers (including importers),
(NAICS codes 325 and 324110), e.g.,
persons who manufacture (defined by
statute to include import) one or more
of the subject chemical substances.
B. What action is the Agency taking?
EPA promulgated a final rule in the
Federal Register of June 29, 2021 (86 FR
34147) (FRL–10020–38) to require
manufacturers (including importers) of
50 specified chemical substances to
report certain lists and copies of
unpublished health and safety studies to
EPA. The chemical substances subject to
this rule are listed in this document and
consist of the 20 designated by EPA as
high-priority substances and the 30
organohalogen flame retardants being
evaluated for risks by the Consumer
Product Safety Commission (CPSC)
under the Federal Hazardous
Substances Act (FHSA), The Agency.is
extending the submission deadline
established in that final rule from
September 27, 2021 to December 1, 2021
for the following chemicals:
• Ethylene Dibromide
• 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8hexamethylcyclopenta [g]-2benzopyran (HHCB)
• Tris(2-chloroethyl) phosphate (TCEP)
• Phthalic Anhydride
• p- Dichlorobenzene
• o-Dichlorobenzene
• Phosphoric acid, triphenyl ester (TPP)
• Di-ethylhexyl phthalate (DEHP)
• 1,2-Dichloroethane
• trans-1,2-Dichloroethylene
• 1,1,2-Trichloroethane
• 1,2-Dichloropropane
E:\FR\FM\01OCR1.SGM
01OCR1
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Rules and Regulations
•
•
•
•
•
•
•
•
1,1-Dichloroethane
1,3-Butadiene
Formaldehyde
Dibutyl phthalate (DBP)
Butyl benzyl phthalate (BBP)
Di-isobutyl phthalate
Dicyclohexyl phthalate
4,4′-(1-Methylethylidene)bis[2, 6dibromophenol] (TBBPA)
EPA is also extending the deadline
established in the June 29, 2021 final
rule from September 27, 2021 to January
25, 2022 for the following chemicals:
• Bis(2-ethylhexyl) tetrabromophthalate
• Bis(hexachlorocyclopentadieno)
cyclooctane
• 1,2-Bis(2,4,6-tribromophenoxy)ethane
• 1,1′-Ethane-1,2diylbis(pentabromobenzene)
• 2-Ethylhexyl-2,3,4,5tetrabromobenzoate
• 2-(2-Hydroxyethoxy)ethyl 2hydroxypropyl 3,4,5,6tetrabromophthalate
• 2,2′-[(1-Methylethylidene)bis[(2,6dibromo-4,1-phenylene)
oxymethylene]]bis[oxirane]
• Mixture of chlorinated linear alkanes
C14–17 with 45–52% chlorine
• N,N-Ethylenebis(tetrabromophthalimide)
• Pentabromochlorocyclohexane
• (Pentabromophenyl)methyl acrylate
• Pentabromotoluene
• Perbromo-1,4-diphenoxybenzene
• Phosphonic acid, (2-chloroethyl)-,
bis(2-chloroethyl) ester
• Phosphoric acid, 2,2bis(chloromethyl)-1,3-propanediyl
tetrakis(2-chloroethyl) ester
• Propanoic acid, 2-bromo-, methyl
ester
• Tetrabromobisphenol A-bis(2,3dibromopropyl ether)
• Tetrabromobisphenol A-bis(2hydroxyethyl) ether
• Tetrabromobisphenol A diallyl ether
• Tetrabromobisphenol A dimethyl
ether
• 2,4,6-Tribromoaniline
• 1,3,5-Tribromo-2-(prop-2-en-1yloxy)benzene
• Tris(2-chloroethyl)phosphite
• Tris(1-chloro-2-propyl)phosphate
• Tris(2-chloro-1-propyl)phosphate
• Tris(2,3-dibromopropyl)phosphate
• 1,3,5-Tris(2,3-dibromopropyl)-1,3,5triazine-2,4,6(1H,3H,5H)-trione
• Tris(1,3-dichloro-2-propyl)phosphate
• Tris(tribromoneopentyl)phosphate
• 2,4,6-Tris-(2,4,6-tribromophenoxy)1,3,5-triazine
C. Why is the Agency taking this action?
The Agency is taking this action to
provide additional time for the
regulated community to familiarize
themselves with new TSCA Health and
VerDate Sep<11>2014
16:40 Sep 30, 2021
Jkt 256001
Safety Data Reporting requirements.
EPA has not added chemicals to the
TSCA section 8(d) rule in a manner that
would affect a large group of
stakeholders since 2006, for the orphan
High Production Volume chemicals.
With respect to the timing of this action,
the need for the Agency to extend the
deadline arose, in part, as a result of
receiving a sizable number of requests to
extend the reporting deadline.
Additionally, the Agency recognizes
that complications exist for certain
entities subject to this rule resulting
from the COVID–19 pandemic, which
can present challenges to accessing
records that may only be available in
hard copy formats (e.g., microfiche).
EPA therefore believes it is
appropriate to extend the reporting
period to allow the regulated
community additional time for data
reporting. EPA is making available a
historic question and answer document
about reporting under TSCA 8(d) and
additional content on its web page for
the rulemaking (available at https://
www.epa.gov/chemicals-under-tsca/
health-and-safety-data-reportingaddition-20-high-priority-substancesand-30), providing reporting entities
additional time to review these
materials and prepare any necessary
submissions to improve reporting
quality for this rule.
EPA’s timeline for risk evaluations
under TSCA section 6 necessitates that
data received via the TSCA section 8(d)
action be received in time for use in risk
evaluations for chemical substances that
have been designated as high-priority
substances. Thus, EPA is limiting the
deadline extension to December 1, 2021
for these chemical substances. Receiving
TSCA section 8(d) submissions on these
high-priority substances by December 1,
2021 will ensure that such information
will be received in time for use in risk
evaluations on these chemical
substances. For the remaining
organohalogen flame retardants subject
to the rule, EPA is extending the
deadline to January 25, 2022.
D. What is the Agency’s authority for
taking this action?
EPA promulgated the Health and
Safety Data Reporting rule under TSCA
section 8(d) (15 U.S.C. 2607(d)), and it
is codified at 40 CFR part 716. EPA is
using this TSCA section 8(d) rule in
accordance with 40 CFR 716.105 to
gather information on chemical
substances. Under section 553(b)(B) of
the Administrative Procedure Act
(APA), 5 U.S.C. 553(b)(B), an agency
may issue a final rule without providing
notice and an opportunity for public
comment if it for good cause finds that
PO 00000
Frm 00049
Fmt 4700
Sfmt 4700
54387
notice and public procedures are
impracticable, unnecessary, or contrary
to the public interest. In this instance,
the Agency finds that notice and public
comment procedures are unnecessary
because this is merely an extension of
the reporting period that does not alter
the substantive TSCA section 8(d)
reporting requirements in any way and
are impracticable because there is
insufficient time for notice and
comment on an extension to the
deadline prior to the reporting deadline,
and EPA only became aware of the need
for the extension upon receiving
numerous requests recently. The
Agency believes the extension will not
result in a significant delay in the
processing and availability of
information to EPA for TSCA section 6
risk evaluations or to Consumer Product
Safety Commission’s (CPSC) evaluation
for risks under the Federal Hazardous
Substances Act (FHSA). Receiving
TSCA section 8(d) submissions
pursuant to these deadlines (i.e.,
December 1, 2021 for the high-priority
substances and January 25, 2022 for the
Organohalogen Flame Retardants) will
ensure that such information will be
received in time for use in these
respective activities (i.e., evaluations
pursuant to TSCA and FHSA). Further,
any impact on the regulated community
is expected to be beneficial to the public
interest given that the extension
provides additional time to submit
complete and accurate unpublished
health and safety studies to EPA.
This final rule is effective
immediately upon publication. Section
553(d)(1) of the Administrative
Procedure Act, 5 U.S.C. 553(d)(1),
provides that final rules shall not
become effective until 30 days after
publication in the Federal Register
‘‘except . . . a substantive rule which
grants or recognizes an exemption or
relieves a restriction.’’ The purpose of
this provision is to ‘‘give affected parties
a reasonable time to adjust their
behavior before the final rule takes
effect.’’ Omnipoint Corp. v. Fed.
Commc’n Comm’n, 78 F.3d 620, 630
(D.C. Cir. 1996); see also United States
v. Gavrilovic, 551 F.2d 1099, 1104 (8th
Cir. 1977) (quoting legislative history).
However, when the agency grants or
recognizes an exemption or relieves a
restriction, affected parties do not need
a reasonable time to adjust because the
effect is not adverse. EPA has
determined that this rule relieves a
restriction because it provides
manufacturers (including importers)
additional time to comply with the
Health and Safety Data Reporting rule.
E:\FR\FM\01OCR1.SGM
01OCR1
54388
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Rules and Regulations
II. Statutory and Executive Order
Reviews
Additional information about these
statutes and Executive Orders can be
found at https://www2.epa.gov/lawsregulations/laws-and-executive-orders.
A. Executive Order 12866: Regulatory
Planning and Review and Executive
Order 13563: Improving Regulation and
Regulatory Review
The Office of Management and Budget
(OMB) has exempted actions under
TSCA section 8(d) related to the Health
and Safety Data Reporting rule from the
requirements of Executive Order 12866
(58 FR 51735, October 4, 1993). As such,
this final rule was not reviewed by OMB
under Executive Orders 12866 and
13563 (76 FR 3821, January 21, 2011).
B. Paperwork Reduction Act (PRA)
This action does not contain any new
or revised information collections
subject to OMB approval under the
PRA, 44 U.S.C. 3501 et seq. Information
collection activities contained in the
TSCA 8(d) rule are already approved by
the Office of Management and Budget
(OMB) under OMB Control No. 2070–
0004.
C. Regulatory Flexibility Act (RFA)
This action is not subject to the RFA,
5 U.S.C. 601 et seq. The RFA applies
only to rules subject to notice and
comment rulemaking requirements
under the APA, 5 U.S.C. 553, or any
other statute. This rule is not subject to
notice and comment requirements
under the APA because the Agency has
invoked the APA ‘‘good cause’’
exemption.
D. Unfunded Mandates Reform Act
(UMRA)
This action will not impose any
enforceable duty or contain any
unfunded mandate as described under
Title II of UMRA, 2 U.S.C. 1531–1538 et
seq.
E. Executive Order 13132: Federalism
This action does not have federalism
implications as specified in Executive
Order 13132 (64 FR 43255, August 10,
1999). It will not have substantial direct
effects on the states, on the relationship
between the national government and
the states, or on the distribution of
power and responsibilities among the
various levels of government.
VerDate Sep<11>2014
16:40 Sep 30, 2021
Jkt 256001
F. Executive Order 13175: Consultation
and Coordination With Indian Tribal
Governments
This action does not have tribal
implications as specified in Executive
Order 13175 (65 FR 67249, November 9,
2000). It will not have substantial direct
effects on tribal governments, on the
relationship between the Federal
government and the Indian tribes, or on
the distribution of power and
responsibilities between the Federal
government and Indian tribes. Thus,
E.O. 13175 does not apply to this action.
G. Executive Order 13045: Protection of
Children From Environmental Health
Risks and Safety Risks
EPA interprets Executive Order 13045
(62 FR 19885, April 23, 1997) as
applying only to those regulatory
actions that concern environmental
health or safety risks that the Agency
has reason to believe may
disproportionately affect children, per
the definition of ‘‘covered regulatory
action’’ in section 2–202 of the
Executive Order. This action is not a
covered regulatory action because it is
not ‘‘economically significant’’ under
Executive Order 12866 and it does not
concern an environmental health risk or
safety risk. Although this action would
not establish an environmental standard
intended to mitigate health or safety
risks, the information that would be
submitted to EPA in accordance with
this rule would be used to inform the
Agency’s decision-making process
regarding chemical substances to which
children may be disproportionately
exposed. This information may also
assist the Agency and others in
determining whether the chemical
substances covered in this proposed
rule present potential risks, which
would allow the Agency and others to
take appropriate action to investigate
and mitigate those risks.
H. Executive Order 13211: Actions
Concerning Regulations That
Significantly Affect Energy Supply,
Distribution, or Use
This action is not a ‘‘significant
energy action’’ as defined in Executive
Order 13211 (66 FR 28355, May 22,
2001) because it is not likely to have a
significant adverse effect on the supply,
distribution, or use of energy and has
not otherwise been designated by the
Administrator of OMB’s Office of
Information and Regulatory Affairs as a
‘‘significant energy action.’’
PO 00000
Frm 00050
Fmt 4700
Sfmt 4700
I. National Technology Transfer and
Advancement Act (NTTAA)
Because this action does not involve
any technical standards, NTTAA section
12(d), 15 U.S.C. 272 note, does not
apply to this action.
J. Executive Order 12898: Federal
Actions To Address Environmental
Justice in Minority Populations and
Low-Income Populations
This action does not entail special
considerations of environmental justice
related issues as delineated by
Executive Order 12898 (59 FR 7629,
February 16, 1994). However, the
Agency believes that the information
collected through this rule will inform
the TSCA risk evaluations that are
planned for these chemicals and will
thereby enable the Agency to better
protect human health and the
environment, including in low-income
and minority communities.
K. Congressional Review Act (CRA)
This action is subject to the CRA (5
U.S.C. 801 et seq.), and EPA will submit
a rule report to each House of the
Congress and to the Comptroller General
of the United States. This action is not
a ‘‘major rule’’ as defined by 5 U.S.C.
804(2).
List of Subjects in 40 CFR Part 716
Environmental protection, Chemicals,
Hazardous substances, Health and
safety, Reporting and recordkeeping
requirements.
Dated: September 23, 2021.
Michal Freedhoff,
Assistant Administrator, Office of Chemical
Safety and Pollution Prevention.
Therefore, for the reasons stated in the
preamble, EPA is amending 40 CFR
chapter I as follows:
PART 716—HEALTH AND SAFETY
DATA REPORTING
1. The authority citation for part 716
continues to read as follows:
■
Authority: 15 U.S.C. 2607(d).
2. In § 716.120(d), amend the table by
revising all the entries under the
headings ‘‘High-Priority Substances’’
and ‘‘Organohalogen flame retardants’’
to read as follows:
■
§ 716.120 Substances and listed mixtures
to which this subpart applies.
*
*
*
(d) * * *
E:\FR\FM\01OCR1.SGM
01OCR1
*
*
54389
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Rules and Regulations
Category
CASRN
*
*
*
*
High-Priority Substances:
1,3-Butadiene ........................................................................................................
Butyl benzyl phthalate (BBP)—1,2-Benzene-dicarboxylic acid, 1-butyl
2(phenylmethyl) ester ........................................................................................
Dibutyl phthalate (DBP) (1,2-Benzene-dicarboxylic acid, 1,2-dibutyl ester) .........
o-Dichlorobenzene ................................................................................................
p-Dichlorobenzene ................................................................................................
1,1-Dichloroethane ................................................................................................
1,2-Dichloroethane ................................................................................................
Trans-1,2-Dichloroethylene ...................................................................................
1,2-Dichloropropane ..............................................................................................
Dicyclohexyl phthalate ..........................................................................................
Di-ethylhexyl phthalate (DEHP)—(1,2-Benzene-dicarboxylic acid, 1,2-bis(2ethylhexyl) ester) ...............................................................................................
Di-isobutyl phthalate (DIBP)—(1,2-Benzene-dicarboxylic acid, 1,2-bis(2methylpropyl) ester) ........................................................................................
Ethylene dibromide ...............................................................................................
Formaldehyde .......................................................................................................
1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta [g]-2-benzopyran
(HHCB) ..............................................................................................................
4,4′-(1-Methylethylidene)bis[2,6-dibromophenol] (TBBPA) ...................................
Phosphoric acid, triphenyl ester (TPP) .................................................................
Phthalic anhydride .................................................................................................
1,1,2-Trichloroethane ............................................................................................
Tris(2-chloroethyl) phosphate (TCEP) ..................................................................
*
*
*
*
*
Organohalogen flame retardants:
Bis(2-ethylhexyl) tetrabromophthalate ..................................................................
Bis(hexachlorocyclopentadieno) cyclooctane .......................................................
1,2-Bis(2,4,6-tribromophenoxy)ethane ..................................................................
1,1′-Ethane-1,2-diylbis(pentabromobenzene) .......................................................
2-Ethylhexyl-2,3,4,5-tetrabromobenzoate .............................................................
2-(2-Hydroxyethoxy)ethyl 2-hydroxypropyl 3,4,5,6-tetrabromophthalate ..............
2,2′-[(1-Methylethylidene)bis[(2,6-dibromo-4,1-phenylene)oxymethylene]]bis[oxirane] ......................................................................
Mixture of chlorinated linear alkanes C14–17 with 45–52% chlorine ..................
N,N-Ethylene-bis(tetrabromophthalimide) .............................................................
Pentabromochlorocyclohexane .............................................................................
(Pentabromophenyl)methyl acrylate .....................................................................
Pentabromotoluene ...............................................................................................
Perbromo-1,4-diphenoxybenzene .........................................................................
Phosphonic acid, (2-chloroethyl)-, bis(2-chloroethyl) ester ..................................
Phosphoric acid, 2,2-bis(chloromethyl)-1,3-propanediyl tetrakis(2-chloroethyl)
ester ...................................................................................................................
Propanoic acid, 2-bromo-, methyl ester ................................................................
Tetrabromobisphenol A-bis(2,3-dibromopropyl ether) ..........................................
Tetrabromobisphenol A bis(2-hydroxyethyl) ether ................................................
Tetrabromobisphenol A diallyl ether .....................................................................
Tetrabromobisphenol A dimethyl ether .................................................................
2,4,6-Tribromoaniline ............................................................................................
1,3,5-Tribromo-2-(prop-2-en-1-yloxy)benzene ......................................................
Tris(2-chloroethyl)phosphite ..................................................................................
Tris(1-chloro-2-propyl)phosphate ..........................................................................
Tris(2-chloro-1-propyl)phosphate ..........................................................................
Tris(2,3-dibromopropyl)phosphate ........................................................................
1,3,5-Tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione ....................
Tris(1,3-dichloro-2-propyl)phosphate ....................................................................
Tris(tribromoneopentyl)phosphate ........................................................................
2,4,6-Tris-(2,4,6-tribromophenoxy)-1,3,5-triazine ..................................................
*
VerDate Sep<11>2014
*
16:40 Sep 30, 2021
*
Jkt 256001
PO 00000
*
Frm 00051
Fmt 4700
Special
exemptions
*
Sunset
date
*
106–99–0
§ 716.21(a)(9)
7/29/21
12/01/21
85–68–7
84–74–2
95–50–1
106–46–7
75–34–3
107–06–2
156–60–5
78–87–5
84–61–7
§
§
§
§
§
§
§
§
§
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
117–81–7
§ 716.21(a)(9)
7/29/21
12/01/21
84–69–5
106–93–4
50–00–0
§ 716.21(a)(9)
§ 716.21(a)(9)
§ 716.21(a)(9)
7/29/21
7/29/21
7/29/21
12/01/21
12/01/21
12/01/21
§
§
§
§
§
§
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
12/01/21
1222–05–5
79–94–7
115–86–6
85–44–9
79–00–5
115–96–8
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
716.21(a)(9)
*
*
*
26040–51–7
13560–89–9
37853–59–1
84852–53–9
183658–27–7
20566–35–2
§
§
§
§
§
§
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
3072–84–2
85535–85–9
32588–76–4
87–84–3
59447–55–1
87–83–2
58965–66–5
6294–34–4
§
§
§
§
§
§
§
§
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
38051–10–4
5445–17–0
21850–44–2
4162–45–2
25327–89–3
37853–61–5
147–82–0
3278–89–5
140–08–9
13674–84–5
6145–73–9
126–72–7
52434–90–9
13674–87–8
19186–97–1
25713–60–4
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
716.21(a)(10)
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
7/29/21
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
1/25/22
*
Sfmt 4700
Effective
date
E:\FR\FM\01OCR1.SGM
*
01OCR1
*
54390
Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Rules and Regulations
Affordable Life-Saving Medications’’
rule. The 2021 NPRM provided for a 30day comment period, and HHS received
332 comments. HHS carefully
considered all comments in developing
this rule, as outlined in Section VI
below, and presents a summary of all
significant comments and HHS
responses.
[FR Doc. 2021–21164 Filed 9–30–21; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
42 CFR Part 51c
RIN 0906–AB30
Implementation of Executive Order on
Access to Affordable Life-Saving
Medications; Rescission of Regulation
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Final rule; rescission of
regulations.
AGENCY:
HHS is rescinding the final
rule entitled ‘‘Implementation of
Executive Order on Access to Affordable
Life-Saving Medications,’’ published in
the December 23, 2020, Federal Register
(2020 Rule). HHS is rescinding the 2020
Rule due to the excessive administrative
costs and burdens that implementation
would have imposed on health centers.
In particular, the 2020 Rule required
health centers to create and maintain
new practices necessary to determine
patients’ eligibility to receive certain
drugs at or below the discounted price
paid by the health center or subgrantees
plus a minimal administration fee. HHS
finds the 2020 Rule’s implementation
would have resulted in reduced
resources available to support critical
services to health center patients—
including those who use insulin and
injectable epinephrine. HHS’s
consideration of the 2020 Rule’s impact
was informed, in part, by the demands
on health centers resulting from the
COVID–19 pandemic. As Executive
Order 13937 remains in effect, HHS is
exploring non-regulatory options to
implement the Executive Order.
DATES: This rule is effective November
1, 2021.
FOR FURTHER INFORMATION CONTACT:
Jennifer Joseph, Director, Office of
Policy and Program Development,
Bureau of Primary Health Care, Health
Resources and Services Administration,
5600 Fishers Lane, Rockville, Maryland
20857; email: jjoseph@hrsa.gov;
telephone: 301–594–4300; fax: 301–
594–4997.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Public Participation
On June 16, 2021, HHS published a
Notice of Proposed Rulemaking (2021
NPRM) in the Federal Register (86 FR
32008) to rescind the ‘‘Implementation
of Executive Order on Access to
VerDate Sep<11>2014
16:40 Sep 30, 2021
Jkt 256001
II. Background
HHS published the subject NPRM in
the Federal Register on September 28,
2020 (85 FR 60748), and the 2020 Rule
on December 23, 2020 (85 FR 83822).
The 2020 Rule established a new
requirement directing all health centers
receiving grants under section 330(e) of
the Public Health Service Act (42 U.S.C.
254b(e)) that participate in the 340B
Program (42 U.S.C. 256b), to the extent
that they plan to make insulin and/or
injectable epinephrine available to their
patients, to provide assurances that they
have established practices to provide
these drugs at or below the discounted
price paid by the health center or
subgrantees under the 340B Program
(plus a minimal administration fee) to
health center patients with low
incomes, as determined by the
Secretary, who have a high cost sharing
requirement for either insulin or
injectable epinephrine; have a high
unmet deductible; or who have no
health insurance.
On June 16, 2021, after a careful
reassessment of the comments
submitted in response to the proposed
rule published at 85 FR 60748
(September 28, 2020) and consideration
of the comments received on the
proposed rule to delay the effective date
published at 86 FR 13872 (March 11,
2021), HHS published the 2021 NPRM
to rescind the 2020 Rule. The 2021
NPRM cited significant concerns
regarding health centers needing to
divert vital resources to implement the
2020 Rule. The 2021 NPRM requested
comment on the administrative burden
and costs to comply with the 2020 Rule
and thus maintain eligibility for future
Health Center Program grants. The 2021
NPRM also requested comment on
whether a rescission would assist health
centers in continuing to provide
primary care services to medically
underserved and vulnerable
populations. HHS noted the
administrative burdens associated with
the 2020 Rule, particularly in light of
health centers’ continuing role in
ensuring equitable access to COVID–19
vaccination and maintaining the
capacity to provide primary and
preventive care that addresses the
ongoing and evolving needs of hard-toreach and disproportionately affected
PO 00000
Frm 00052
Fmt 4700
Sfmt 4700
populations. HHS also noted that the
2020 Rule would carry increased
administrative costs and administrative
burden and would result in reduced
resources being available to support
services to health center patients. In
addition, most comments submitted
previously noted that, in many cases,
health centers already voluntarily
provided medications at reduced prices
to their patients.
The 2021 NPRM comment period
ended on July 16, 2021. After review
and consideration of all submitted
comments, HHS has concluded that the
2020 Rule created excessive
administrative burden for health
centers, which in turn would have
resulted in reduced resources for health
center patient services. HHS has
determined that the overall impacts of
the administrative burden outweigh
benefits to patients from the reduction
in prices of insulin and injectable
epinephrine. Therefore, HHS is issuing
this final rule rescinding the 2020 Rule,
which was published at 85 FR 83822.
The 2020 Rule became effective on
July 20, 2021, prior to publication of
this rescission. Due to the timing of
Health Center Program funding, grants
awarded in Fiscal Year 2022 would be
the first opportunity for HRSA to
impose the requirements of the
‘‘Implementation of Executive Order on
Access to Affordable Life-Saving
Medications’’ rule, and so the
requirements have not yet been
implemented.
III. Statutory Authority
The statement of authority for 42 CFR
part 51c cites to sections 330 (42 U.S.C.
254b) and 215 of the Public Health
Service Act, (42 U.S.C. 216),
respectively.
IV. Overview of This Rule
HHS is rescinding the 2020 Rule and
therefore deleting the associated
revision to the regulations codified at 42
CFR 51c.303(w). 42 CFR 51c.303(w)
stated: ‘‘To the extent that an applicant
for funding under Section 330(e) of the
Public Health Service Act (42 U.S.C.
254b(e)) has indicated that it plans to
distribute, either directly, or through a
written agreement, drugs purchased
through the 340B Drug Pricing Program
(42 U.S.C. 256b), and to the extent that
such applicant plans to make insulin
and/or injectable epinephrine available
to its patients, the applicant shall
provide an assurance that it has
established practices to provide insulin
and injectable epinephrine at or below
the discounted price paid by the health
center grantee or subgrantee under the
340B Drug Pricing Program (plus a
E:\FR\FM\01OCR1.SGM
01OCR1
]]>Agencies
[Federal Register Volume 86, Number 188 (Friday, October 1, 2021)]
[Rules and Regulations]
[Pages 54386-54390]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21164]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 716
[EPA-HQ-OPPT-2020-0474; FRL-8204-02-OCSPP]
RIN 2070-AB11
Health and Safety Data Reporting; Addition of 20 High-Priority
Substances and 30 Organohalogen Flame Retardants; Extension of
Submission Deadline
AGENCY: Environmental Protection Agency (EPA).
ACTION: Final rule; extension of submission deadline.
-----------------------------------------------------------------------
SUMMARY: EPA is amending the deadline for reporting pursuant to the
Toxic Substances Control Act (TSCA) Health and Safety Data Reporting
rule, which requires manufacturers (including importers) of 50
specified chemical substances to report certain lists and copies of
unpublished health and safety studies to EPA. Specifically, EPA will be
amending the deadline from September 27, 2021 to December 1, 2021 for
20 of the 50 chemical substances and to January 25, 2022 for 30 of the
50 chemical substances. The Health and Safety Data Reporting Rule,
promulgated pursuant to TSCA section 8(d), requires manufacturers
(including importers) of certain chemical substances to submit lists
and copies of certain unpublished health and safety studies to EPA.
DATES: This final rule is effective October 1, 2021.
ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPPT-2020-0474, is available at
https://www.regulations.gov or at the Office of Pollution Prevention
and Toxics Docket (OPPT Docket), Environmental Protection Agency Docket
Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334, 1301
Constitution Ave. NW, Washington, DC.
Please note that due to the public health concerns related to
COVID-19, the EPA Docket Center (EPA/DC) and Reading Room is closed to
visitors with limited exceptions. The staff continues to provide remote
customer service via email, phone, and webform. For the latest status
information on the EPA/DC and docket access, visit https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
For technical information contact: Virginia Lee, Data Collections
Branch, Data Gathering and Analysis Division (7410M), Office of
Pollution Prevention and Toxics, Environmental Protection Agency, 1200
Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number:
(202) 564-4142; email address: [email protected].
For general information contact: The TSCA-Hotline, ABVI-Goodwill,
422 South Clinton Ave., Rochester, NY 14620; telephone number: (202)
554-1404; email address: [email protected].
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by this action if you manufacture
(defined by statute to include import) any of the chemical substances
that are listed in 40 CFR 716.120(d) of the regulatory text of this
document. The following list of North American Industrial
Classification System (NAICS) codes is not intended to be exhaustive,
but rather provides a guide to help readers determine whether this
document applies to them. Potentially affected entities may include:
Chemical manufacturers (including importers), (NAICS codes 325 and
324110), e.g., persons who manufacture (defined by statute to include
import) one or more of the subject chemical substances.
B. What action is the Agency taking?
EPA promulgated a final rule in the Federal Register of June 29,
2021 (86 FR 34147) (FRL-10020-38) to require manufacturers (including
importers) of 50 specified chemical substances to report certain lists
and copies of unpublished health and safety studies to EPA. The
chemical substances subject to this rule are listed in this document
and consist of the 20 designated by EPA as high-priority substances and
the 30 organohalogen flame retardants being evaluated for risks by the
Consumer Product Safety Commission (CPSC) under the Federal Hazardous
Substances Act (FHSA), The Agency.is extending the submission deadline
established in that final rule from September 27, 2021 to December 1,
2021 for the following chemicals:
Ethylene Dibromide
1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta [g]-2-
benzopyran (HHCB)
Tris(2-chloroethyl) phosphate (TCEP)
Phthalic Anhydride
p- Dichlorobenzene
o-Dichlorobenzene
Phosphoric acid, triphenyl ester (TPP)
Di-ethylhexyl phthalate (DEHP)
1,2-Dichloroethane
trans-1,2-Dichloroethylene
1,1,2-Trichloroethane
1,2-Dichloropropane
[[Page 54387]]
1,1-Dichloroethane
1,3-Butadiene
Formaldehyde
Dibutyl phthalate (DBP)
Butyl benzyl phthalate (BBP)
Di-isobutyl phthalate
Dicyclohexyl phthalate
4,4'-(1-Methylethylidene)bis[2, 6-dibromophenol] (TBBPA)
EPA is also extending the deadline established in the June 29, 2021
final rule from September 27, 2021 to January 25, 2022 for the
following chemicals:
Bis(2-ethylhexyl) tetrabromophthalate
Bis(hexachlorocyclopentadieno) cyclooctane
1,2-Bis(2,4,6-tribromophenoxy)ethane
1,1'-Ethane-1,2-diylbis(pentabromobenzene)
2-Ethylhexyl-2,3,4,5-tetrabromobenzoate
2-(2-Hydroxyethoxy)ethyl 2-hydroxypropyl 3,4,5,6-
tetrabromophthalate
2,2'-[(1-Methylethylidene)bis[(2,6-dibromo-4,1-
phenylene)oxymethylene]]bis[oxirane]
Mixture of chlorinated linear alkanes C14-17 with 45-52%
chlorine
N,N-Ethylene-bis(tetrabromophthalimide)
Pentabromochlorocyclohexane
(Pentabromophenyl)methyl acrylate
Pentabromotoluene
Perbromo-1,4-diphenoxybenzene
Phosphonic acid, (2-chloroethyl)-, bis(2-chloroethyl) ester
Phosphoric acid, 2,2-bis(chloromethyl)-1,3-propanediyl
tetrakis(2-chloroethyl) ester
Propanoic acid, 2-bromo-, methyl ester
Tetrabromobisphenol A-bis(2,3-dibromopropyl ether)
Tetrabromobisphenol A-bis(2-hydroxyethyl) ether
Tetrabromobisphenol A diallyl ether
Tetrabromobisphenol A dimethyl ether
2,4,6-Tribromoaniline
1,3,5-Tribromo-2-(prop-2-en-1-yloxy)benzene
Tris(2-chloroethyl)phosphite
Tris(1-chloro-2-propyl)phosphate
Tris(2-chloro-1-propyl)phosphate
Tris(2,3-dibromopropyl)phosphate
1,3,5-Tris(2,3-dibromopropyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-
trione
Tris(1,3-dichloro-2-propyl)phosphate
Tris(tribromoneopentyl)phosphate
2,4,6-Tris-(2,4,6-tribromophenoxy)-1,3,5-triazine
C. Why is the Agency taking this action?
The Agency is taking this action to provide additional time for the
regulated community to familiarize themselves with new TSCA Health and
Safety Data Reporting requirements. EPA has not added chemicals to the
TSCA section 8(d) rule in a manner that would affect a large group of
stakeholders since 2006, for the orphan High Production Volume
chemicals. With respect to the timing of this action, the need for the
Agency to extend the deadline arose, in part, as a result of receiving
a sizable number of requests to extend the reporting deadline.
Additionally, the Agency recognizes that complications exist for
certain entities subject to this rule resulting from the COVID-19
pandemic, which can present challenges to accessing records that may
only be available in hard copy formats (e.g., microfiche).
EPA therefore believes it is appropriate to extend the reporting
period to allow the regulated community additional time for data
reporting. EPA is making available a historic question and answer
document about reporting under TSCA 8(d) and additional content on its
web page for the rulemaking (available at https://www.epa.gov/chemicals-under-tsca/health-and-safety-data-reporting-addition-20-high-priority-substances-and-30), providing reporting entities additional
time to review these materials and prepare any necessary submissions to
improve reporting quality for this rule.
EPA's timeline for risk evaluations under TSCA section 6
necessitates that data received via the TSCA section 8(d) action be
received in time for use in risk evaluations for chemical substances
that have been designated as high-priority substances. Thus, EPA is
limiting the deadline extension to December 1, 2021 for these chemical
substances. Receiving TSCA section 8(d) submissions on these high-
priority substances by December 1, 2021 will ensure that such
information will be received in time for use in risk evaluations on
these chemical substances. For the remaining organohalogen flame
retardants subject to the rule, EPA is extending the deadline to
January 25, 2022.
D. What is the Agency's authority for taking this action?
EPA promulgated the Health and Safety Data Reporting rule under
TSCA section 8(d) (15 U.S.C. 2607(d)), and it is codified at 40 CFR
part 716. EPA is using this TSCA section 8(d) rule in accordance with
40 CFR 716.105 to gather information on chemical substances. Under
section 553(b)(B) of the Administrative Procedure Act (APA), 5 U.S.C.
553(b)(B), an agency may issue a final rule without providing notice
and an opportunity for public comment if it for good cause finds that
notice and public procedures are impracticable, unnecessary, or
contrary to the public interest. In this instance, the Agency finds
that notice and public comment procedures are unnecessary because this
is merely an extension of the reporting period that does not alter the
substantive TSCA section 8(d) reporting requirements in any way and are
impracticable because there is insufficient time for notice and comment
on an extension to the deadline prior to the reporting deadline, and
EPA only became aware of the need for the extension upon receiving
numerous requests recently. The Agency believes the extension will not
result in a significant delay in the processing and availability of
information to EPA for TSCA section 6 risk evaluations or to Consumer
Product Safety Commission's (CPSC) evaluation for risks under the
Federal Hazardous Substances Act (FHSA). Receiving TSCA section 8(d)
submissions pursuant to these deadlines (i.e., December 1, 2021 for the
high-priority substances and January 25, 2022 for the Organohalogen
Flame Retardants) will ensure that such information will be received in
time for use in these respective activities (i.e., evaluations pursuant
to TSCA and FHSA). Further, any impact on the regulated community is
expected to be beneficial to the public interest given that the
extension provides additional time to submit complete and accurate
unpublished health and safety studies to EPA.
This final rule is effective immediately upon publication. Section
553(d)(1) of the Administrative Procedure Act, 5 U.S.C. 553(d)(1),
provides that final rules shall not become effective until 30 days
after publication in the Federal Register ``except . . . a substantive
rule which grants or recognizes an exemption or relieves a
restriction.'' The purpose of this provision is to ``give affected
parties a reasonable time to adjust their behavior before the final
rule takes effect.'' Omnipoint Corp. v. Fed. Commc'n Comm'n, 78 F.3d
620, 630 (D.C. Cir. 1996); see also United States v. Gavrilovic, 551
F.2d 1099, 1104 (8th Cir. 1977) (quoting legislative history). However,
when the agency grants or recognizes an exemption or relieves a
restriction, affected parties do not need a reasonable time to adjust
because the effect is not adverse. EPA has determined that this rule
relieves a restriction because it provides manufacturers (including
importers) additional time to comply with the Health and Safety Data
Reporting rule.
[[Page 54388]]
II. Statutory and Executive Order Reviews
Additional information about these statutes and Executive Orders
can be found at https://www2.epa.gov/laws-regulations/laws-and-executive-orders.
A. Executive Order 12866: Regulatory Planning and Review and Executive
Order 13563: Improving Regulation and Regulatory Review
The Office of Management and Budget (OMB) has exempted actions
under TSCA section 8(d) related to the Health and Safety Data Reporting
rule from the requirements of Executive Order 12866 (58 FR 51735,
October 4, 1993). As such, this final rule was not reviewed by OMB
under Executive Orders 12866 and 13563 (76 FR 3821, January 21, 2011).
B. Paperwork Reduction Act (PRA)
This action does not contain any new or revised information
collections subject to OMB approval under the PRA, 44 U.S.C. 3501 et
seq. Information collection activities contained in the TSCA 8(d) rule
are already approved by the Office of Management and Budget (OMB) under
OMB Control No. 2070-0004.
C. Regulatory Flexibility Act (RFA)
This action is not subject to the RFA, 5 U.S.C. 601 et seq. The RFA
applies only to rules subject to notice and comment rulemaking
requirements under the APA, 5 U.S.C. 553, or any other statute. This
rule is not subject to notice and comment requirements under the APA
because the Agency has invoked the APA ``good cause'' exemption.
D. Unfunded Mandates Reform Act (UMRA)
This action will not impose any enforceable duty or contain any
unfunded mandate as described under Title II of UMRA, 2 U.S.C. 1531-
1538 et seq.
E. Executive Order 13132: Federalism
This action does not have federalism implications as specified in
Executive Order 13132 (64 FR 43255, August 10, 1999). It will not have
substantial direct effects on the states, on the relationship between
the national government and the states, or on the distribution of power
and responsibilities among the various levels of government.
F. Executive Order 13175: Consultation and Coordination With Indian
Tribal Governments
This action does not have tribal implications as specified in
Executive Order 13175 (65 FR 67249, November 9, 2000). It will not have
substantial direct effects on tribal governments, on the relationship
between the Federal government and the Indian tribes, or on the
distribution of power and responsibilities between the Federal
government and Indian tribes. Thus, E.O. 13175 does not apply to this
action.
G. Executive Order 13045: Protection of Children From Environmental
Health Risks and Safety Risks
EPA interprets Executive Order 13045 (62 FR 19885, April 23, 1997)
as applying only to those regulatory actions that concern environmental
health or safety risks that the Agency has reason to believe may
disproportionately affect children, per the definition of ``covered
regulatory action'' in section 2-202 of the Executive Order. This
action is not a covered regulatory action because it is not
``economically significant'' under Executive Order 12866 and it does
not concern an environmental health risk or safety risk. Although this
action would not establish an environmental standard intended to
mitigate health or safety risks, the information that would be
submitted to EPA in accordance with this rule would be used to inform
the Agency's decision-making process regarding chemical substances to
which children may be disproportionately exposed. This information may
also assist the Agency and others in determining whether the chemical
substances covered in this proposed rule present potential risks, which
would allow the Agency and others to take appropriate action to
investigate and mitigate those risks.
H. Executive Order 13211: Actions Concerning Regulations That
Significantly Affect Energy Supply, Distribution, or Use
This action is not a ``significant energy action'' as defined in
Executive Order 13211 (66 FR 28355, May 22, 2001) because it is not
likely to have a significant adverse effect on the supply,
distribution, or use of energy and has not otherwise been designated by
the Administrator of OMB's Office of Information and Regulatory Affairs
as a ``significant energy action.''
I. National Technology Transfer and Advancement Act (NTTAA)
Because this action does not involve any technical standards, NTTAA
section 12(d), 15 U.S.C. 272 note, does not apply to this action.
J. Executive Order 12898: Federal Actions To Address Environmental
Justice in Minority Populations and Low-Income Populations
This action does not entail special considerations of environmental
justice related issues as delineated by Executive Order 12898 (59 FR
7629, February 16, 1994). However, the Agency believes that the
information collected through this rule will inform the TSCA risk
evaluations that are planned for these chemicals and will thereby
enable the Agency to better protect human health and the environment,
including in low-income and minority communities.
K. Congressional Review Act (CRA)
This action is subject to the CRA (5 U.S.C. 801 et seq.), and EPA
will submit a rule report to each House of the Congress and to the
Comptroller General of the United States. This action is not a ``major
rule'' as defined by 5 U.S.C. 804(2).
List of Subjects in 40 CFR Part 716
Environmental protection, Chemicals, Hazardous substances, Health
and safety, Reporting and recordkeeping requirements.
Dated: September 23, 2021.
Michal Freedhoff,
Assistant Administrator, Office of Chemical Safety and Pollution
Prevention.
Therefore, for the reasons stated in the preamble, EPA is amending
40 CFR chapter I as follows:
PART 716--HEALTH AND SAFETY DATA REPORTING
0
1. The authority citation for part 716 continues to read as follows:
Authority: 15 U.S.C. 2607(d).
0
2. In Sec. 716.120(d), amend the table by revising all the entries
under the headings ``High-Priority Substances'' and ``Organohalogen
flame retardants'' to read as follows:
Sec. 716.120 Substances and listed mixtures to which this subpart
applies.
* * * * *
(d) * * *
[[Page 54389]]
----------------------------------------------------------------------------------------------------------------
Special Effective Sunset
Category CASRN exemptions date date
----------------------------------------------------------------------------------------------------------------
* * * * * * *
High-Priority Substances:
1,3-Butadiene...................................... 106-99-0 Sec. 7/29/21 12/01/21
716.21(a)(9)
Butyl benzyl phthalate (BBP)--1,2-Benzene- 85-68-7 Sec. 7/29/21 12/01/21
dicarboxylic acid, 1-butyl 2(phenylmethyl) ester.. 716.21(a)(9)
Dibutyl phthalate (DBP) (1,2-Benzene-dicarboxylic 84-74-2 Sec. 7/29/21 12/01/21
acid, 1,2-dibutyl ester).......................... 716.21(a)(9)
o-Dichlorobenzene.................................. 95-50-1 Sec. 7/29/21 12/01/21
716.21(a)(9)
p-Dichlorobenzene.................................. 106-46-7 Sec. 7/29/21 12/01/21
716.21(a)(9)
1,1-Dichloroethane................................. 75-34-3 Sec. 7/29/21 12/01/21
716.21(a)(9)
1,2-Dichloroethane................................. 107-06-2 Sec. 7/29/21 12/01/21
716.21(a)(9)
Trans-1,2-Dichloroethylene......................... 156-60-5 Sec. 7/29/21 12/01/21
716.21(a)(9)
1,2-Dichloropropane................................ 78-87-5 Sec. 7/29/21 12/01/21
716.21(a)(9)
Dicyclohexyl phthalate............................. 84-61-7 Sec. 7/29/21 12/01/21
716.21(a)(9)
Di-ethylhexyl phthalate (DEHP)--(1,2-Benzene- 117-81-7 Sec. 7/29/21 12/01/21
dicarboxylic acid, 1,2-bis(2-ethylhexyl) ester)... 716.21(a)(9)
Di-isobutyl phthalate (DIBP)--(1,2-Benzene- 84-69-5 Sec. 7/29/21 12/01/21
dicarboxylic acid, 1,2-bis-(2methylpropyl) ester). 716.21(a)(9)
Ethylene dibromide................................. 106-93-4 Sec. 7/29/21 12/01/21
716.21(a)(9)
Formaldehyde....................................... 50-00-0 Sec. 7/29/21 12/01/21
716.21(a)(9)
1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8- 1222-05-5 Sec. 7/29/21 12/01/21
hexamethylcyclopenta [g]-2-benzopyran (HHCB)...... 716.21(a)(9)
4,4'-(1-Methylethylidene)bis[2,6-dibromophenol] 79-94-7 Sec. 7/29/21 12/01/21
(TBBPA)........................................... 716.21(a)(9)
Phosphoric acid, triphenyl ester (TPP)............. 115-86-6 Sec. 7/29/21 12/01/21
716.21(a)(9)
Phthalic anhydride................................. 85-44-9 Sec. 7/29/21 12/01/21
716.21(a)(9)
1,1,2-Trichloroethane.............................. 79-00-5 Sec. 7/29/21 12/01/21
716.21(a)(9)
Tris(2-chloroethyl) phosphate (TCEP)............... 115-96-8 Sec. 7/29/21 12/01/21
716.21(a)(9)
* * * * * * *
Organohalogen flame retardants:
Bis(2-ethylhexyl) tetrabromophthalate.............. 26040-51-7 Sec. 7/29/21 1/25/22
716.21(a)(10)
Bis(hexachlorocyclopentadieno) cyclooctane......... 13560-89-9 Sec. 7/29/21 1/25/22
716.21(a)(10)
1,2-Bis(2,4,6-tribromophenoxy)ethane............... 37853-59-1 Sec. 7/29/21 1/25/22
716.21(a)(10)
1,1'-Ethane-1,2-diylbis(pentabromobenzene)......... 84852-53-9 Sec. 7/29/21 1/25/22
716.21(a)(10)
2-Ethylhexyl-2,3,4,5-tetrabromobenzoate............ 183658-27-7 Sec. 7/29/21 1/25/22
716.21(a)(10)
2-(2-Hydroxyethoxy)ethyl 2-hydroxypropyl 3,4,5,6- 20566-35-2 Sec. 7/29/21 1/25/22
tetrabromophthalate............................... 716.21(a)(10)
2,2'-[(1-Methylethylidene)bis[(2,6-dibromo-4,1- 3072-84-2 Sec. 7/29/21 1/25/22
phenylene)oxymethylene]]bis[oxirane].............. 716.21(a)(10)
Mixture of chlorinated linear alkanes C14-17 with 85535-85-9 Sec. 7/29/21 1/25/22
45-52% chlorine................................... 716.21(a)(10)
N,N-Ethylene-bis(tetrabromophthalimide)............ 32588-76-4 Sec. 7/29/21 1/25/22
716.21(a)(10)
Pentabromochlorocyclohexane........................ 87-84-3 Sec. 7/29/21 1/25/22
716.21(a)(10)
(Pentabromophenyl)methyl acrylate.................. 59447-55-1 Sec. 7/29/21 1/25/22
716.21(a)(10)
Pentabromotoluene.................................. 87-83-2 Sec. 7/29/21 1/25/22
716.21(a)(10)
Perbromo-1,4-diphenoxybenzene...................... 58965-66-5 Sec. 7/29/21 1/25/22
716.21(a)(10)
Phosphonic acid, (2-chloroethyl)-, bis(2- 6294-34-4 Sec. 7/29/21 1/25/22
chloroethyl) ester................................ 716.21(a)(10)
Phosphoric acid, 2,2-bis(chloromethyl)-1,3- 38051-10-4 Sec. 7/29/21 1/25/22
propanediyl tetrakis(2-chloroethyl) ester......... 716.21(a)(10)
Propanoic acid, 2-bromo-, methyl ester............. 5445-17-0 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tetrabromobisphenol A-bis(2,3-dibromopropyl ether). 21850-44-2 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tetrabromobisphenol A bis(2-hydroxyethyl) ether.... 4162-45-2 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tetrabromobisphenol A diallyl ether................ 25327-89-3 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tetrabromobisphenol A dimethyl ether............... 37853-61-5 Sec. 7/29/21 1/25/22
716.21(a)(10)
2,4,6-Tribromoaniline.............................. 147-82-0 Sec. 7/29/21 1/25/22
716.21(a)(10)
1,3,5-Tribromo-2-(prop-2-en-1-yloxy)benzene........ 3278-89-5 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tris(2-chloroethyl)phosphite....................... 140-08-9 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tris(1-chloro-2-propyl)phosphate................... 13674-84-5 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tris(2-chloro-1-propyl)phosphate................... 6145-73-9 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tris(2,3-dibromopropyl)phosphate................... 126-72-7 Sec. 7/29/21 1/25/22
716.21(a)(10)
1,3,5-Tris(2,3-dibromopropyl)-1,3,5-triazine- 52434-90-9 Sec. 7/29/21 1/25/22
2,4,6(1H,3H,5H)-trione............................ 716.21(a)(10)
Tris(1,3-dichloro-2-propyl)phosphate............... 13674-87-8 Sec. 7/29/21 1/25/22
716.21(a)(10)
Tris(tribromoneopentyl)phosphate................... 19186-97-1 Sec. 7/29/21 1/25/22
716.21(a)(10)
2,4,6-Tris-(2,4,6-tribromophenoxy)-1,3,5-triazine.. 25713-60-4 Sec. 7/29/21 1/25/22
716.21(a)(10)
* * * * * * *
----------------------------------------------------------------------------------------------------------------
[[Page 54390]]
[FR Doc. 2021-21164 Filed 9-30-21; 8:45 am]
BILLING CODE 6560-50-P
